Base Pair Biotechnologies, Inc. Market Research Report

Background

Company Overview

Base Pair Biotechnologies, Inc. is a privately held biotechnology company specializing in the discovery and development of aptamers—short, single-stranded DNA or RNA molecules that can bind specifically to a wide range of targets, including proteins, small molecules, and cells. Founded in 2012, the company is headquartered in Pearland, Texas, strategically located near major medical centers and universities.

Mission and Vision

The company's mission is to make a lasting difference in the world by solving customer problems through the creation of novel affinity agents that empower healthcare solutions and protect the planet. Base Pair Biotechnologies envisions advancing aptamer technology to address critical needs within the scientific community, thereby contributing to the improvement of global health and environmental sustainability.

Industry Significance

Aptamers offer several advantages over traditional antibodies, including smaller size, ease of synthesis, and the ability to target a broader range of molecules. This positions Base Pair Biotechnologies as a significant player in the biotechnology sector, particularly in diagnostics, therapeutics, and environmental testing. The company's expertise in aptamer development has led to collaborations with various academic, commercial, and government institutions, enhancing its industry presence.

Key Strategic Focus

Core Objectives

Base Pair Biotechnologies aims to provide highly customized aptamer discovery and development services, focusing on delivering novel affinity agents that meet specific client needs across various applications. The company emphasizes a collaborative approach, working closely with clients to understand project objectives and technical challenges.

Areas of Specialization

The company specializes in the development of aptamers for a diverse range of targets, including proteins, small molecules, and cells. Applications of these aptamers span diagnostics, therapeutics, environmental testing, and veterinary medicine. Base Pair Biotechnologies is particularly adept at creating novel affinity agents with high selectivity and affinity for small molecules, such as toxins, metabolites, and drugs.

Key Technologies Utilized

Base Pair employs a patented multiplex selection process that reduces time and cost for aptamer discovery. This process facilitates the development of specific and pan-binders to related targets. Additionally, the company utilizes proprietary aptamer libraries containing novel modifications to modulate binding properties and increase conformational diversity. Proprietary techniques for developing aptamers to small molecules and novel methods for determining solution-phase affinity are also integral to their technology platform.

Primary Markets Targeted

Base Pair Biotechnologies serves a diverse range of customer segments, including pharmaceutical and biopharmaceutical companies, diagnostics, environmental testing, and veterinary medicine. The company's flexible business model offers services ranging from the purchase of previously developed aptamers to custom aptamer and assay development, and exclusive licensing of specific aptamer sequences.

Financials and Funding

Funding History

As of November 2017, Base Pair Biotechnologies completed a $3.2 million Series A-3 financing round. The round was led by Eventi Capital Partners and Base Pair Canada, with participation from BioTex and Ashok Gowda, BioTex’s President & CEO, one of Base Pair’s founders. The funds were allocated to acquire new laboratory instruments and technology to expand cellular and molecular analysis capabilities, enabling improved methods for finding aptamers that bind targets on and in live cells. The investment also supported team expansion and enhanced geographical reach.

Recent Funding Rounds

The most recent funding round was completed in October 2023, with the National Institutes of Health (NIH) providing a grant titled "Aptamer engineering of lentiviral vectors for cardiac gene therapies." This grant supports the development of aptamers to guide viral vectors specifically to the heart, aiming to address challenges in delivering gene therapies for genetic heart diseases.

Notable Investors

Notable investors include Eventi Capital Partners, Base Pair Canada, BioTex, and Ashok Gowda. The NIH grant in 2023 further underscores the company's credibility and potential in the biotechnology sector.

Utilization of Capital

The capital from the Series A-3 financing round was utilized to acquire new laboratory instruments and technology, expand the team, and enhance geographical reach. The NIH grant is being used to develop aptamers for targeted gene therapy delivery to cardiac tissues.

Pipeline Development

Key Pipeline Candidates

Base Pair Biotechnologies is involved in the development of aptamers for various applications, including diagnostics, therapeutics, and environmental testing. A notable project includes the development of aptamers to guide lentiviral vectors specifically to the heart, aiming to address challenges in delivering gene therapies for genetic heart diseases.

Stages of Development

The company is engaged in the discovery and development stages of aptamers, with ongoing projects in collaboration with academic, commercial, and government institutions. Specific details on the stages of development for individual pipeline candidates are not publicly disclosed.

Target Conditions

Target conditions for aptamer development include various diseases and conditions where aptamers can serve as diagnostic tools, therapeutic agents, or environmental sensors. The recent NIH grant focuses on genetic heart diseases, specifically hypertrophic cardiomyopathy.

Anticipated Milestones

Anticipated milestones include the successful development and application of aptamers in diagnostics, therapeutics, and environmental testing. The NIH grant project aims to develop aptamers for targeted gene therapy delivery to cardiac tissues, with timelines not specified in the available information.

Technological Platform and Innovation

Proprietary Technologies

• Multiplex Selection Process: A patented method that reduces time and cost for aptamer discovery, facilitating the development of specific and pan-binders to related targets.

• Proprietary Aptamer Libraries: Libraries containing novel modifications to modulate binding properties and increase conformational diversity.

• AptaTracker™ Tool: A proprietary tool that enables clients to closely monitor each stage of the aptamer development process.

Significant Scientific Methods

• VENN Multiplex™ SELEX: A proprietary method for identifying aptamer sandwich pairs for ELASA and lateral flow methods.

• Novel Methods for Solution Phase Affinity Determination: Techniques developed to determine the affinity of aptamers in solution, enhancing the selection process.

AI-Driven Capabilities

While specific AI-driven capabilities are not detailed in the available information, Base Pair Biotechnologies employs advanced bioinformatics and chemical modification techniques to develop high-affinity and selective nucleic acid aptamers.

Leadership Team

Key Executives

• Bill Jackson, Ph.D.: Founder and Chief Scientist. Dr. Jackson has served as Principal Investigator on over $5 million in Small Business Innovation Research grants and is a recognized leader in the aptamer space, having authored twelve peer-reviewed publications on aptamers.

• Vicki Singer: President and CEO. Ms. Singer has been instrumental in leading the company through significant growth phases and has a background in biotechnology management.

• Christopher Quan, Esq.: General Counsel. Mr. Quan has over 12 years of experience in intellectual property and legal segments in biotechnology, dental, and engineering small companies, with extensive work in patent prosecution, research and development practices, and intellectual property licensing.

• Ashok Gowda: Co-Founder and Board Member. Mr. Gowda is the President & CEO of BioTex, Inc., one of Base Pair's founders, and has been involved in the biotechnology sector for several years.

Leadership Changes

Specific details on recent significant changes or appointments within the company's leadership are not publicly disclosed.

Competitor Profile

Market Insights and Dynamics

The biotechnology sector, particularly in aptamer development, is characterized by rapid innovation and a growing demand for alternatives to traditional antibodies. Aptamers offer advantages such as smaller size, ease of synthesis, and the ability to target a broader range of molecules, positioning companies like Base Pair Biotechnologies favorably in the market.

Competitor Analysis